Biogen and partner Eisai Co., Ltd. have submitted a Biologics License Application (BLA) to the U.S. FDA for aducanumab, an investigational treatment for Alzheimer’s disease. The submission followed ongoing collaboration with the FDA and includes clinical data from the Phase III EMERGE and ENGAGE studies, as well as the Phase 1b PRIME study. Biogen has requested Priority Review. If approved, aducanumab would become the first therapy to reduce the clinical decline of Alzheimer’s diseas...